X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - TAIPEITIMES.COM - A La Une - 30/Nov 00:00

Clinical phase needed for all doctors

Articles similaires

Sorry! Image not available at this time

Clinical phase needed for all doctors

taipeitimes.com - 30/Nov 00:00

Sorry! Image not available at this time

Any Canadian who asks for HIV prevention drugs should get them, doctors say

wn.com - 02/Dec 00:50

For the first time since 2017, Canadian doctors have released updated clinical guidelines for antiretroviral medications used to prevent HIV. ......

Sorry! Image not available at this time

Any Canadian who asks for HIV prevention drugs should get them, doctors say

wn.com - 02/Dec 00:50

For the first time since 2017, Canadian doctors have released updated clinical guidelines for antiretroviral medications used to prevent HIV. ......

Sorry! Image not available at this time

Imagion Biosystems on track for Phase 2 breast cancer clinical trial early next year

stockhead.com.au - 01/Dec 20:17

Imagion Biosystems is on track for IND submission this month and a Phase 2 clinical trial in the US early ...

Sorry! Image not available at this time

LTR Pharma gains ethics approval for ED nasal spray phase II study, targets patient recruitment in early 2026

stockhead.com.au - 03/Dec 03:34

LTR Pharma receives HREC approval from Bellberry for its SPONTAN erectile dysfunction nasal spray Phase II clinical study. ...

Sorry! Image not available at this time

Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)

mangaloremirror.com - 28/Nov 00:37

Eydenzelt® a biosimilar referencing Eylea®, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the...

Sorry! Image not available at this time

Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)

mangaloremirror.com - 28/Nov 00:37

Eydenzelt® a biosimilar referencing Eylea®, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the...

Sorry! Image not available at this time

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

wn.com - 07/Dec 00:43

VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)...

Sorry! Image not available at this time

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

wn.com - 07/Dec 00:43

VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)...

Sorry! Image not available at this time

Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD

wn.com - 01/Dec 14:37

BOSTON--(BUSINESS WIRE)--Dec 1, 2025-- ......

Les derniers communiqués